March 23, 2020 Columns by Ed Tobias MS News that Caught My Eye Last Week: Coronavirus and DMTs, Gilenya and Pediatric MS, Ponesimod for RRMS, Cannabis for Spasticity I’m starting this week by linking to our Coronavirus COVID-19 Information section on the Multiple Sclerosis News Today Forums. My fellow moderator, John Connor, and I have been posting information there from our news writers and columnists about the evolving situation. Have You Tested Positive for Coronavirus…
March 6, 2020 Columns by Ed Tobias FDA Approval of Investigational DMT Ozanimod May Be Weeks Away By the end of this month, another disease-modifying therapy (DMT) for multiple sclerosis may be available in the U.S. Ozanimod is an investigational daily pill for the treatment of relapsing MS. The Food and Drug Administration is expected to decide…
January 2, 2020 News by Iqra Mumal, MSc Use of DMTs Changing ‘Natural History’ of Relapsing MS, Study Says People with relapsing multiple sclerosis (MS) have a better prognosis and a slower progression to disability since the introduction of disease-modifying treatments (DMTs) some 20 years ago, according to a retrospective study. The study, āOutcomes in a Modern Cohort of Treated Multiple Sclerosis Patients Followed from Diagnosis Up…
November 4, 2019 Columns by Ed Tobias MS News that Caught My Eye Last Week: Vumerity Approval, Low Antibody Levels in MS Patients, GA Depot Trial, Tecfidera Study Vumerity Approved in US as Treatment for RRMS and Active SPMS By my count, Vumerity is the 18th disease-modifying therapy (DMT) that the U.S. Food and Drug Administration (FDA) has approved for multiple sclerosis (MS). It’s one of very few approved for secondary progressive MS (SPMS). I find…
October 17, 2019 News by Patricia Inacio, PhD Rituximab Linked to Greater Risk of Infections in MS Patients in Real-world Swedish Study Newer disease-modifying treatments for multiple sclerosis (MS) are effective but also known to carry a greater risk of infections in a patient group already more likely to be troubled by infections ā and this higher risk is particularly evident in treatment with rituximab, a DMT often used off-label in…
September 23, 2019 News by Marisa Wexler, MS EMD Serono Opening Phase 3 Trials of Oral Evobrutinib in Relapsing MS Patients EMD Serono (Merck KGaA in Germany) is opening two pivotal and global Phase 3 clinical trials to evaluate the effectiveness and safety of oral evobrutinibĀ in people with relapsing multiple sclerosis (MS). Evobrutinib, also known as M2951, works by blocking a protein called Brutonās tyrosine kinase (BTK), which is…
December 17, 2018 Columns by Ed Tobias MS News that Caught My Eye Last Week: Cannabis, Switching Interferons, Brain Stimulation by Smartphone, Lipoic Acid MS Patients Report Beneficial Effects of Cannabis with Few Side Effects, Survey Shows This survey agrees with what I’ve found in my limited experience with cannabis (in my case, CBD oil). A small amount can ease some of my spasticity and help me to get a better…